Abbott Laboratories and Deltanoid Pharmaceuticals entered into an option and licence agreement to develop novel Vitamin D Receptor Activators (VDRAs) for treating chronic kidney disease. The analyst states that this deal benifits both Deltanoid and Abbott. This deal would provide Deltanoid with increased revenues and add further credibility to its vitamin D therapies. Also, the deal provides potential next-generation follow-up compounds for Zemplar and strengthens the company’s research portfolio in the area of chronic kidney disease.